Join CBSET and our partner Cilcare at the Safety Pharmacology Society Northeast Regional Meeting, May 1, from 9:00 AM to 4:00 PM, hosted by Takeda, 35 Landsdown Street, Cambridge, Massachusetts.
This year’s meeting theme is Emerging Innovative Approaches to Therapeutic Risk Mitigation in Safety Pharmacology and Beyond. The 2024 Boston Regional Meeting is this Spring’s best local opportunity for networking and hearing the latest developments from academia, CROs, industry, and FDA.
REGISTER HERE
CBSET presentations include:
Student/Young Investigator/Academic Networking, Donald Hodges PhD, MSc, DSP, Study Director, session co-chair. 8:00 - 9:00 am.
Neural and Cardiac Biomarker Applications for Preclinical Testing. Hayden Dillow, BS, MS, Pathology Technician. 11:00 - 11:30 am.
Poster: Your Pathologist is a Tool! Nicola Parry, BSc, MSc, BVSc, DACVP, FRCVS, Director of Pathology Laboratory Operations.
Cilcare presentations include:
Ototoxic Treatments in Cochlear Cultures. Carolanne Coyat, PhD, Anatomy & Physiology Senior Scientist. 10:15 - 10:45 am.
Intra-cochlear Delivery for Gene Therapy in Rodents. Sebastien Diot, R&D Project Manager, Anatomy & Physiology Scientist. 2:45 - 3:15 pm.
Keynote speakers include:
Heart-on-a-Chip for Modeling Disease and Toxicity, Kevin Shani, PhD student at Harvard. 9:15 - 10:15 am.
Ventricular assist devices and the pig cardiogenic shock model, Steven Keller, MD, PhD, Assistant Professor of Medicine Johns Hopkins, Co-founder X-COR Therapeutics. 1:00 - 2:00 pm. Dr. Keller’s presentation will include results from collaborative work performed at CBSET.
Related Scientific Publications:
Dynamic load modulation predicts right heart tolerance of left ventricular cardiovascular assist in a porcine model of cardiogenic shock. Kimberly K. Lamberti, Steven P. Keller, Elazer R. Edelman. Science Translational Medicine. 2024 Feb 14;16(734):eadk4266. doi: 10.1126/scitranslmed.adk4266.
Decreased LPS-induced lung injury in pigs treated with a lung surfactant protein A-derived nonapeptide that inhibits peroxiredoxin 6 activity. Aron B. Fisher, Brett Zani, Thomas Han, Chandra Dodia, Raffaele Melidone, Steven Keller. American Journal of Physiology: Lung Cellular and Molecular Physiology. 13 Feb 2024 https://doi.org/10.1152/ajplung.00325.2023.
HEAR THIS! Potential Therapeutics for COVID-19 Should Be Tested for Auditory Safety Wahid Awad, PhD, Chief Business Officer, CILcare and Michael Naimark, Director of Business Development, CBSET, Inc. World Pharma Today, August 24, 2020
Auditory Therapy, Ototoxicity, and GLP Compliance: Will the promising market for ear disorder treatments follow ophthalmology’s dramatic growth curve? Michael Naimark, CBSET, and Marie-Pierre Pasdelou, CILcare. World Pharma Today, November 1, 2017